Meeting
2020 Genitourinary Cancers Symposium
Abiraterone acetate (AA) with or without cabazitaxel (CBZ) in treatment of chemotherapy naive metastatic castration-resistant prostate cancer (mCRPC).
Authors
Susan F. Slovin
Memorial Sloan Kettering Cancer Center, New York, NY
Susan F. Slovin , Karen E. Knudsen , Susan Halabi , Mark T. Fleming , Ana M. Molina , Steven Paul Wolf , Renee de Leeuw , Celina Fernandez , Praneet Kang , Traci Southwell , Carol L. Jones , Escarleth Fernandez , William Kevin Kelly
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02218606
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 84)
Abstract #
84
Poster Bd #
D8
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Circulating tumor cells (CTCs) N-terminal androgen receptor expression to identify patients (pts) with castrate resistant prostate cancer (CRPC) who are more sensitive to chemotherapy.
First Author: Susan F. Slovin
Poster
2023 ASCO Genitourinary Cancers Symposium
Androgen receptor (AR) mutations in men with metastatic castration-resistant prostate cancer (mCRPC): Incidence and natural history.
First Author: Alice Bernard-Tessier
Poster
2021 Genitourinary Cancers Symposium
18F-fluciclovine positron emission tomography (PET) in metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate.
First Author: Pedro C. Barata
Poster
2018 Genitourinary Cancers Symposium
A randomized phase II study comparing cabazitaxel/prednisone to cabazitaxel alone for second-line chemotherapy in men with metastatic castrate resistant prostate cancer (mCRPC): CABACARE.
First Author: Carlo Buonerba